Dr. Reem Z. Sharaiha still remembers the first patient who came to her clinic asking not just to lose weight, but to reclaim her life. That conversation, years ago, helped shape what is now a transformative vision for obesity care—one that goes far beyond the latest blockbuster drugs. Today, as co-author of a pivotal update to the POWER framework published in Gastroenterology, Sharaiha is helping redefine how medicine treats obesity in the era of GLP-1s like semaglutide and tirzepatide. These medications have undeniably reshaped expectations, offering some patients 15–20% weight loss with a weekly injection. But as the new guidelines make clear, pills and pens alone aren’t the full solution to a complex, chronic disease affecting over 40% of U.S. adults.
The updated POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework, originally launched in 2017 and now refreshed for 2026, reflects a seismic shift in how specialists approach obesity. It moves decisively away from BMI as the sole measure of risk, embracing the concept of “clinical obesity”—a chronic, systemic condition that requires individualized, long-term care. This is especially critical for gastroenterologists and hepatologists, who routinely treat obesity-related complications like metabolic dysfunction-associated steatotic liver disease (MASLD), GERD, and gallbladder disorders. The new guidelines position these specialists not just as bystanders, but as central players in a multidisciplinary care model.
Among the most promising advances: endoscopic bariatric and metabolic therapies, such as endoscopic sleeve gastroplasty (ESG), which now have robust evidence supporting their use. ESG, which reshapes the stomach without surgery, has shown sustained weight loss of up to 18% at two years. Even more compelling is the emerging data on combining therapies—using GLP-1 medications alongside endoscopic or surgical interventions. Early results suggest these combinations can produce greater and more durable weight loss than any single approach. At NewYork-Presbyterian/Weill Cornell Medicine, where Sharaiha leads endoscopic bariatric therapies, this integrated model is already changing outcomes.
Equally transformative is the rise of precision medicine. Genetic insights are beginning to help clinicians predict which patients will respond best to medications, endoscopic procedures, or surgery—moving away from trial-and-error toward tailored treatment plans. This is not just about weight loss; it’s about preventing disease, improving quality of life, and recognizing obesity as the chronic condition it is.
The message is clear: the future of obesity care is not one-size-fits-all, but a layered, compassionate, and science-driven strategy. As new tools emerge, the focus remains on the patient—not the number on the scale, but the person behind it.